Boundless Bio, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
ADAR1 Capital Management and Daniel Schneeberger have filed a joint Schedule 13G, reporting beneficial ownership of 8.8% of Boundless Bio, Inc. common stock as of June 30, 2026.
NASDAQ
Citadel entities have updated their beneficial ownership filings for Boundless Bio, Inc., reporting a combined 0.6% stake.
NASDAQ
Tang Capital Management, LLC and affiliated entities have reported beneficial ownership of 11.3% of Boundless Bio, Inc.'s common stock.
NASDAQ
FMR LLC and Abigail P. Johnson have reported a 12.0% beneficial ownership stake in Boundless Bio Inc's common stock as of December 31, 2025.
NASDAQ
Citadel Advisors, Citadel Securities, and Kenneth Griffin have disclosed beneficial ownership of Boundless Bio, Inc. common stock, with Griffin holding 6.4% of the outstanding shares.
NASDAQ
RA Capital Management and its affiliates have reported zero beneficial ownership in Boundless Bio, Inc., indicating a complete divestment of their prior holdings.